Snowball logo
logo
AVCT_logo

Avacta Group Plc

AVCTF • PINK
$0.8535$0.00  (0%)
Estimate
EPS
-0.12
Beta
-0.158
Growth
Revenue, YoY
-99.5%
Net income, YoY
-42.56%
FCF, YoY
-10.39%
About the company
Ticker
AVCTF
ISIN
Country
United Kingdom
Sector (GICS)
Healthcare
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.

Frequently asked questions

What sector does Avacta Group Plc (AVCTF) operate in?

Avacta Group Plc belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Avacta Group Plc (AVCTF) current stock price?

As of the latest data, Avacta Group Plc stock price is $0.85, with a previous close of $0.85.

What is Avacta Group Plc (AVCTF) current market capitalization?

Avacta Group Plc market cap is approximately 373.52 million.

What is Avacta Group Plc (AVCTF) Earnings Per Share (EPS)?

The trailing EPS is -$0.12.

What is Avacta Group Plc (AVCTF) EBITDA?

Avacta Group Plc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -14.11 million.

Does Avacta Group Plc (AVCTF) pay dividends?

No. Avacta Group Plc does not pay a dividend.

What is Avacta Group Plc (AVCTF) beta (volatility) score?

Avacta Group Plc has a beta of -0.158, indicating lower volatility than the overall market.